Piper Jaffray Reiterates Overweight On ResMed

Piper Jaffray is reiterating its Overweight rating and $37 price target on shares of ResMed Inc. RMD. In a note to clients, Piper Jaffray writes, "ResMed announced the acquisition of BiancaMed, a private, Northern Ireland based company offering non-contact sleep and breathing monitoring technology for use in the home. BiancaMed currently offers two products: BiancaBaby, a non-contact respiratory sensor for infants; and Sleepminder, a non-contact sleep and respiration sensor and software for adult sleep monitoring. The transaction has already closed and is expected to be ~$0.04 dilutive to F2012 EPS. Given the recent formation of the ResMed Ventures and Initiatives group and the company's significant cash balance ($671M as of 3/31/11), we anticipate additional tuck-in, sleep-focused acquisitions going forward. We reiterate our Overweight rating and $37 price target on RMD shares." Shares of RMD are up 6 cents to $31.09, a gain of 0.2%.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!